Gemcitabine with radiation for locally advanced cervical cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether adding gemcitabine (a chemotherapy medicine) to standard radiation can better treat locally advanced cervical cancer. It also focuses on whether this treatment is safe and effective for people with reduced kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a written consent form and follow study visits and tests.
- You are a woman age 18 to 70, and if you can become pregnant you must have a negative pregnancy test and use approved birth control during treatment and for 12 weeks after.
- Your cervical cancer is stage IB2 to IVA, and it is smaller than 2 cm, with or without nearby para-aortic lymph nodes.
- Your biopsy confirms a specific type of cervical cancer (squamous, adenosquamous, adenocarcinoma, or “glassy cells”).
- You have not had treatment before, and you must be medically able to receive gemcitabine.
- Your kidneys are weaker than average (measured kidney filtration rate under 60), and your blood counts, liver tests, and chest X-ray are within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) given alongside radiation therapy for people with locally advanced cervical cancer. The goal is to see if this combination is safe and effective in shrinking the cancer and improving outcomes.
This trial looks at whether adding chemotherapy after standard chemoradiation helps people with locally advanced cervical cancer. You may be eligible if your MRI after treatment still shows leftover tumor areas and your health and blood tests are within required limits.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
This trial tests whether adding a drug called CB-839 to standard chemoradiation (cisplatin and radiation) can improve outcomes for people with advanced cervical cancer when it cannot be treated with surgery. It aims to see if this combination is safe and effective.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.